TIOTROPIUM BROMIDE INHALATION SPRAY
Manufacturer: Boehringer Ingelheim Pharmaceuticals, Inc.
Score: 141.0
Spiriva Respimat is an anticholinergic inhalation spray used for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD) and for reducing COPD exacerbations. It is also used for the long-term, once-daily, maintenance treatment of asthma in patients 6 years of age and older. The recommended dosage for patients with COPD is 2 inhalations of Spiriva Respimat 2.5 mcg per actuation once-daily, and for patients with asthma, it is 2 inhalations of Spiriva Respimat 1.25 mcg per actuation once-daily. Important safety information includes warnings about immediate hypersensitivity reactions, paradoxical bronchospasm, and worsening of narrow-angle glaucoma and urinary retention. Contraindications include hypersensitivity to tiotropium, ipratropium, or any component of the product.
Risk of immediate hypersensitivity reactions, paradoxical bronchospasm, and worsening of narrow-angle glaucoma and urinary retention
No dosage adjustment is required for geriatric, hepatically-impaired, or renally-impaired patients
2 inhalations of Spiriva Respimat 2.5 mcg per actuation once-daily
Not applicable
2 inhalations of Spiriva Respimat 1.25 mcg per actuation once-daily
2 inhalations of Spiriva Respimat 1.25 mcg per actuation once-daily for patients 6 years of age and older